Abstract: In some embodiments, the invention provides a non-addictive analgesic co-formulation comprising an opioid agonist in an amount sufficient to confer analgesia in a mammalian subject (such as a human) and a neutral opioid antagonist in an amount sufficient to inhibit peripheral effects of the opioid agonist, and insufficient to block substantial central effects of the opioid agonist in the subject. The formulation may be formulated for oral administration to the subject. Such formulations, and methods of using the same, may also deter diversion, inhibit peripheral effects of the opioid agonist, and reduce addiction liability.
Type:
Grant
Filed:
May 15, 2014
Date of Patent:
June 23, 2015
Assignee:
AIKO Biotechnology
Inventors:
Wolfgang Sadée, Edward Bilsky, Janet Yancey-Wrona
Abstract: In some embodiments, the invention provides a non-addictive analgesic co-formulation comprising an opioid agonist in an amount sufficient to confer analgesia in a mammalian subject (such as a human) and a neutral opioid antagonist in an amount sufficient to inhibit peripheral effects of the opioid agonist, and insufficient to block substantial central effects of the opioid agonist in the subject. The formulation may be formulated for oral administration to the subject. Such formulations, and methods of using the same, may also deter diversion, inhibit peripheral effects of the opioid agonist, and reduce addiction liability.
Type:
Application
Filed:
May 15, 2014
Publication date:
November 13, 2014
Applicant:
AIKO Biotechnology
Inventors:
Wolfgang Sadée, Edward Bilsky, Janet Yancey-Wrona
Abstract: A non-addictive analgesic co-formulation comprising an opioid agonist in an amount sufficient to confer analgesia in a mammalian subject and a neutral opioid antagonist in an amount sufficient to inhibit peripheral effects, and insufficient to block substantial central effects, of the opioid agonist in the subject. Such formulations, and methods of using same, may also deter diversion, inhibit peripheral effects, and reduce addiction liability.
Type:
Grant
Filed:
October 17, 2008
Date of Patent:
November 11, 2014
Assignee:
AIKO Biotechnology
Inventors:
Wolfgang Sadée, Edward Bilsky, Janet Yancey-Wrona
Abstract: In some embodiments, the invention provides a non-addictive analgesic co-formulation comprising an opioid agonist in an amount sufficient to confer analgesia in a mammalian subject (such as a human) and a neutral opioid antagonist in an amount sufficient to inhibit peripheral effects of the opioid agonist, and insufficient to block substantial central effects of the opioid agonist in the subject. The formulation may be formulated for oral administration to the subject. Such formulations, and methods of using the same, may also deter diversion, inhibit peripheral effects of the opioid agonist, and reduce addiction liability.
Type:
Grant
Filed:
November 28, 2012
Date of Patent:
June 10, 2014
Assignee:
AIKO Biotechnology
Inventors:
Wolfgang Sadée, Edward Bilsky, Janet Yancey-Wrona
Abstract: In some embodiments, the invention provides a non-addictive analgesic co-formulation comprising an opioid agonist in an amount sufficient to confer analgesia in a mammalian subject (such as a human) and a neutral opioid antagonist in an amount sufficient to inhibit peripheral effects of the opioid agonist, and insufficient to block substantial central effects of the opioid agonist in the subject. The formulation may be formulated for oral administration to the subject. Such formulations, and methods of using the same, may also deter diversion, inhibit peripheral effects of the opioid agonist, and reduce addiction liability.
Abstract: Methods of utilizing an opioid agonist in a mammalian subject in a manner that inhibits peripheral effects of the opioid agonist are described. The methods comprise administering the opioid agonist in an amount sufficient to confer analgesia the subject and co-administering a neutral opioid antagonist or pharmaceutically acceptable isomorph or pharmaceutically acceptable salt thereof in an amount sufficient to substantially inhibit peripheral effects and insufficient to block substantial central effects of the opioid agonist in the subject.
Type:
Application
Filed:
July 18, 2011
Publication date:
November 10, 2011
Applicant:
AIKO BIOTECHNOLOGY
Inventors:
Wolfgang Sadée, Edward Bilsky, Janet Yancey-Wrona
Abstract: A non-addictive analgesic co-formulation comprising an opioid agonist in an amount sufficient to confer analgesia in a mammalian subject and a neutral opioid antagonist in an amount sufficient to inhibit peripheral effects, and insufficient to block substantial central effects, of the opioid agonist in the subject. Such formulations, and methods of using same, may also deter diversion, inhibit peripheral effects, and reduce addiction liability.
Type:
Application
Filed:
October 17, 2008
Publication date:
April 30, 2009
Applicant:
AIKO Biotechnology
Inventors:
Wolfgang Sadee, Edward Bilsky, Janet Yancey-Wrona